Cargando…
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
There are no effective medical treatments for WHO grade III (anaplastic) meningioma. Patients with this high-grade malignancy have a median survival of less than two years. Therapeutics that modulate the mechanisms that inhibit local immune responses in the tumor microenvironment are showing signifi...
Autores principales: | Du, Ziming, Abedalthagafi, Malak, Aizer, Ayal A., McHenry, Allison R., Sun, Heather H., Bray, Mark-Anthony, Viramontes, Omar, Machaidze, Revaz, Brastianos, Priscilla K., Reardon, David A., Dunn, Ian F., Freeman, Gordon J., Ligon, Keith L., Carpenter, Anne E., Alexander, Brian M., Agar, Nathalie Y., Rodig, Scott J., Bradshaw, Elizabeth M., Santagata, Sandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467109/ https://www.ncbi.nlm.nih.gov/pubmed/25609200 |
Ejemplares similares
-
Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma
por: Zhu, Hongda, et al.
Publicado: (2019) -
Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling
por: Mei, Yu, et al.
Publicado: (2017) -
A molecularly integrated grade for meningioma
por: Driver, Joseph, et al.
Publicado: (2021) -
Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5
por: Abedalthagafi, Malak S., et al.
Publicado: (2014) -
Radiographic prediction of meningioma grade by semantic and radiomic features
por: Coroller, Thibaud P., et al.
Publicado: (2017)